Pancreatic Cancer Research

Clinical trialPhase 1Completed

A Study to Investigate 14C-bemcentinib in Healthy Male Subjects

A Phase 1, Open-label, Nonrandomized Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects

Outcome
Results posted; single-arm, no comparison
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
2 August 2022
Ended
23 September 2022
Enrollment
6 participants
Sites
1
Primary outcomes
Total Radioactivity - Plasma Maximum Observed Concentration (Cmax); Total Radioactivity - Whole Blood Maximum Observed Concentration (Cmax); Plasma Pharmacokinetic Parameters Bemcentinib - Maximum Observed Concentration (Cmax); Plasma Pharmacokinetic Parameters Bemcentinib - Time to Maximum Observed Concentration (Tmax); Plasma Pharmacokinetic Parameters Bemcentinib - Terminal Elimination Half-life (t1/2)
Sponsor type
Industry
Results posted
29 January 2025
Last update
29 January 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 29 January 2025
Primary outcome
Total Radioactivity - Plasma Maximum Observed Concentration (Cmax)Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib: 81.2 (26.8), n = 6Values: geometric mean ngEq/mL, Geometric Coefficient of VariationTime frame: Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-doseNo analysis posted for this outcome (outcome 1)
Primary outcome
Total Radioactivity - Whole Blood Maximum Observed Concentration (Cmax)Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib: 121 (21.6), n = 6Values: geometric mean ngEq/mL, Geometric Coefficient of VariationTime frame: Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-doseNo analysis posted for this outcome (outcome 2)
Primary outcome
Plasma Pharmacokinetic Parameters Bemcentinib - Maximum Observed Concentration (Cmax)Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib: 55.8 (23.5), n = 6Values: geometric mean ng/mL, Geometric Coefficient of VariationTime frame: Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-doseNo analysis posted for this outcome (outcome 3)
Primary outcome
Plasma Pharmacokinetic Parameters Bemcentinib - Time to Maximum Observed Concentration (Tmax)Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib: 12.0 (12.0 to 36.0), n = 6Values: median Hour, Full RangeTime frame: Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-doseNo analysis posted for this outcome (outcome 4)
Primary outcome
Plasma Pharmacokinetic Parameters Bemcentinib - Terminal Elimination Half-life (t1/2)Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib: 92.0 (5.3), n = 6Values: geometric mean Hour, Geometric Coefficient of VariationTime frame: Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-doseNo analysis posted for this outcome (outcome 5)
Primary outcome
Plasma Pharmacokinetic Parameters Bemcentinib - Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞)Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib: 6050 (12.3), n = 6Values: geometric mean h*ng/mL, Geometric Coefficient of VariationTime frame: Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-doseNo analysis posted for this outcome (outcome 6)
Primary outcome
Plasma Pharmacokinetic Parameters Bemcentinib - Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast)Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib: 5550 (13.3), n = 6Values: geometric mean h*ng/mL, Geometric Coefficient of VariationTime frame: Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-doseNo analysis posted for this outcome (outcome 7)
Participants
Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib: 6 started, 6 completed
Serious adverse events
Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib: 0 of 6Participants with at least one serious adverse event, of those at risk, as posted
5 secondary outcomes
Number of Participants With Adverse Events
Single Dose Cohort - 200 mg Containing… 3/6 [Participants]
Number of Participants Who Report a Change From Normal Range Values for Laboratory Safety…
Single Dose Cohort - 200 mg Containing… 0/6 [Participants]
Number of Participants Who Report a Change From Normal Range Values for Any of the Associ…
Single Dose Cohort - 200 mg Containing… 0/6 [Participants]
Number of Participants Who Report a Change From Normal Range Values for Any of the Vital …
Single Dose Cohort - 200 mg Containing… 0/6 [Participants]
Number of Participants Who Report a Change From Normal With Respect to Physical Examinati…
Single Dose Cohort - 200 mg Containing… 0/6 [Participants]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The aims of this Study were to determine: * How much of the Study Drug (bemcentinib) ends up in urine and faeces * How much of the Study Drug and its breakdown products get into the bloodstream * The breakdown products (metabolites) of the Study Drug * The safety of the Study Drug and any side effects that might be associated with it.

Detailed description public domain (ClinicalTrials.gov)

This was a Phase 1, open-label, nonrandomized, single oral dose study in up to 8 healthy male subjects (with 6 required to complete the study). Potential subjects were screened to assess their eligibility to enter the study within 28 days prior to dose administration. Up to 8 subjects were enrolled to ensure that 6 subjects completed the study. Subjects were admitted into the study site on Day -1. On the morning of Day 1, all subjects received a single oral dose of 200 mg containing approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib, 30 minutes after starting a standard high-fat breakfast. Subjects were confined to the study site until at least Day 8. Subjects were discharged from the study site on Day 8 if the following discharge criteria were met: ·≥90% mass balance recovery, and ·\<1% of the total radioactive dose is recovered in combined excreta (urine and feces)in 2 consecutive 24-hour periods. If these discharge criteria were not met by Day 8, subjects were required to remain resident until discharge criteria are met, up to Day 15. If criteria were not met by Day 15, subjects were asked to collect 24-hour excreta samples on up to 2 further occasions on a nonresidential basis to allow extrapolation of urinary and fecal excretion. If needed, the 2 additional 24-hour nonresidential collections started on the morning of Days 22 and 29 (to be brought into the study site at the end of the collection interval on Days 23 and 30, respectively). If on the second occasion the subject still did not meet the desired criterion, then the subject was discharged from the study, per investigator and sponsor decision. Subjects experiencing emesis during the first 4 hours post-dose were discharged on the same day from the study site, provided there were no safety concerns, and after discharge study procedures were performed. The total duration of study participation for each subject (from screening to outpatient visit \[if required\]) was anticipated to be a maximum of approximately 58 days.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Total Radioactivity - Plasma Maximum Observed Concentration (Cmax) [Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose]. Geometric Mean, ngEq/mL (Geometric Coefficient of Variation). Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 81.2 (26.8).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Total Radioactivity - Whole Blood Maximum Observed Concentration (Cmax) [Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose]. Geometric Mean, ngEq/mL (Geometric Coefficient of Variation). Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 121 (21.6).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Plasma Pharmacokinetic Parameters Bemcentinib - Maximum Observed Concentration (Cmax) [Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose]. Geometric Mean, ng/mL (Geometric Coefficient of Variation). Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 55.8 (23.5).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Plasma Pharmacokinetic Parameters Bemcentinib - Time to Maximum Observed Concentration (Tmax) [Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose]. Median, Hour (Full Range). Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 12.0 (12.0 to 36.0).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Plasma Pharmacokinetic Parameters Bemcentinib - Terminal Elimination Half-life (t1/2) [Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose]. Geometric Mean, Hour (Geometric Coefficient of Variation). Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 92.0 (5.3).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Plasma Pharmacokinetic Parameters Bemcentinib - Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) [Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose]. Geometric Mean, h*ng/mL (Geometric Coefficient of Variation). Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 6050 (12.3).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Plasma Pharmacokinetic Parameters Bemcentinib - Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) [Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose]. Geometric Mean, h*ng/mL (Geometric Coefficient of Variation). Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 5550 (13.3).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants With Adverse Events [Collection of AEs occurs through ad hoc reporting from the participants from the point of signature of informed consent through to study completion (up to 5 weeks).]. Count Of Participants, Participants. Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 3.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants Who Report a Change From Normal Range Values for Laboratory Safety Parameters (Serum Biochemistry, Serum Haematology or Urinalysis) From First Dose on Day 1 to Study Completion. [From Day 1 to study completion (up to 5 weeks)]. Count Of Participants, Participants. Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 0.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants Who Report a Change From Normal Range Values for Any of the Associated 12-Lead ECG Parameters From First Dose on Day 1 to Study Completion. [From Day 1 to study completion (up to 5 weeks)]. Count Of Participants, Participants. Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 0.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants Who Report a Change From Normal Range Values for Any of the Vital Signs Parameters From First Dose on Day 1 to Study Completion. [From Day 1 to study completion (up to 5 weeks)]. Count Of Participants, Participants. Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 0.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants Who Report a Change From Normal With Respect to Physical Examination Parameters From First Dose on Day 1 to Study Completion. [From Day 1 to study completion (up to 5 weeks)]. Count Of Participants, Participants. Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib (n=6): 0.